Novel Biomarkers and the Diagnosis of Prion DiseasesSaima Zafar*, Neelam Younus and Inga Zerr
Department of Neurology, Clinical Dementia Center and DZNE, Georg-August University, University Medical Center Goettingen (UMG), Robert-Koch-Str. 40, 37075, Goettingen, Germany
- *Corresponding Author:
- Saima Zafar
Department of Neurology
Clinical Dementia Center and DZNE
University Medical Centre Goettingen
37075, Goettingen, Germany
E-mail: [email protected], saima.zafar@ med.uni-goettingen.de
Received date: September 30, 2015; Accepted date: November 23, 2015; Published date: November 26, 2015
Citation: Zafar S, Younus N, Zerr I (2015) Novel Biomarkers and the Diagnosis of Prion Diseases. J Mol Biomarkers Diagn S8:011. doi:10.4172/2155-9929.S8-011
Copyright: © 2015 Zafar S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
In fatal neurodegenerative diseases, prion diseases have high risk of transmission ability and no cure and effective treatment. This abnormal folded protein disease in brain pose a serious threat to public health and the development of early diagnostic markers and new therapeutic approaches is in pronounced plea. Prion disease show infectious and incurable irrepressible nature and long period of silent incubations and nature of prion diseases, development of early diagnostic markers is in great demand to prevent a potential spread of the disease and for early diagnosis of the disease given the long incubation periods of disease. Moreover discovery of novel biomarkers can lead to development of new therapeutic targets and better understanding of the underlying pathogenesis of the Prion diseases.